COMMUNIQUÉS West-GlobeNewswire

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
18/01/2024
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today [...]
Kane Biotech Announces Special Meeting of Shareholders
18/01/2024
WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special [...]
Aimei Health Technology Co., Ltd. Announces the Separate Trading of its Ordinary Shares and Rights Commencing January 22, 2024
18/01/2024
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd. (“Aimei”) announced today that, commencing January 22, 2024, holders of the units sold in the Company’s initial public offering completed on [...]
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
18/01/2024
DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 [...]
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
18/01/2024
Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant [...]
PHAXIAM Therapeutics annonce son niveau de trésorerie à fin 2023 et son calendrier financier 2024
18/01/2024
Lyon (France) et Cambridge (MA, US), le 18 janvier 2024 – 22h05 CET – PHAXIAM Therapeutics (Nasdaq & Euronext : FR0011471135), annonce aujourd’hui sa trésorerie au 31 décembre 2023 et son calendrier financier pour [...]
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million
18/01/2024
Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to [...]
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
18/01/2024
BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer [...]
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
18/01/2024
– Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated 12 to 16 weeks post [...]
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
18/01/2024
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology [...]
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
18/01/2024
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel immuno-oncology agent with [...]
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
18/01/2024
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 [...]
Celularity Releases CEO Letter to Shareholders
18/01/2024
FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can [...]
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
18/01/2024
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the [...]
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)
18/01/2024
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Equal Partnership with AFT Pharmaceuticals for Development of a Drug Releasing Mucoadhesive Film for VLS (HY-091) Limited [...]
Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV)
18/01/2024
Co-Partenariat avec AFT Pharmaceuticals pour le Développement d'un Film Muco-adhésif Libérant des Médicaments pour le LSV (HY-091) Disponibilité Limitée des Options Thérapeutiques Approuvées dans les LSV Liège, Belgique [...]
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
18/01/2024
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January [...]
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18/01/2024
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReOpen2) FDA [...]
Pressure BioSciences Reports New Client Launching Around UltraShear Nanoemulsions Platform with $300,000-plus Product Order
18/01/2024
VICAR Holdings LLC to Purchase Over 10,000 Bottles of PBIO’s Best-in-Class Nano-CBD Topical Spray in 2024; Aided by the Recent Acquisition of Its New Uncle Buds Business Unit, PBIO Expects Consumer Products to Continue [...]

Pages